[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fertility-preservation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fertility-preservation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,47,75,105,127,144,180,204,251,276,303,331,361,394,418,443,472,497,524],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642837","a-modular-cloud-platform-for-fertility-preservation-100642837",false,"NCT07642531","A Modular Cloud Platform For Fertility Preservation","A Modular CLoud Based Platform To Enhance Fertility Preservation Awareness: Design, Pilot Testing And Randomized Controlled Trial","Inclusion Criteria:\n\n* Women of reproductive age between the ages of 18 and 45,\n* Diagnosed with early stage cervical cancer, ovarian cancer, tubal cancer and endometrial cancer and whose treatment has not started,\n* Those who have a smartphone and can use the platform,\n* Volunteering and giving informed consent,\n* Turkish literate,\n* Individuals who do not report mental problems\n* Do not have children,\n* Marital status is married or single.\n\nExclusion Criteria:\n\n* Neurological disease (e.g., stroke, multiple sclerosis) or cognitive impairment,\n* Advanced-stage gynecologic cancers,\n* Failure to complete the follow-up period,\n* Initiation of oncologic treatment during the study period,\n* Non-completion or incomplete completion of the data collection instruments,\n* Non-use of the platform among participants allocated to the intervention group,\n* History of prior cancer treatment.","FEMALE","18 Years","45 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","The research was designed as a randomized controlled study to determine the effectiveness of a modular cloud-based training platform in increasing awareness of fertility preservation.\n\nThe study aims to develop a free, modular, cloud-based, sustainable digital platform to increase fertility awareness. The platform will provide basic information on fertility preservation methods in plain language to support informed decisions. Content will be based on European Society of Human Reproduction and Embryology (ESHRE) , International Federation of Gynaecology and Obstetrics (FIGO) and Asian Society of Gynecologic Oncology (ASCO) guidelines. The study targets not only cancer patients but also women requesting fertility preservation for medical or social reasons.\n\nIn the first stage, the platform will be designed with the ADDIE instructional design model (Analysis, Design, Development, Implementation, Evaluation) and content created per international guidelines. In the second stage, the prototype will be pilot-tested and revised. In the third stage, effectiveness will be tested through a randomized controlled trial. Educational modules will be provided to the intervention group, while the control group will receive brochures. The study will include women aged 18-45 with early-stage gynecological cancer (cervix, ovary, tube, endometrium) at Prof. Dr. Cemil Tascioglu City Hospital, untreated. Participants must have Turkish literacy and internet access. Sample size, calculated with G\\*Power, is 140 total (70 per group).",[27,28],"Fertility Preservation","Gynecologic Cancers",[30,31,32,33],"fertility","gynecologic cancer","fertility preservation","mobile application","NOT_YET_RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":21},"2026-09-02",{"date":42,"type":21},"2027-01-01",{"name":44,"class":45},"Biruni University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100574795","phase-4-intranasal-nafarelin-for-triggering-oocyte-maturation-100574795","NCT06763926","Intranasal Nafarelin For Triggering Oocyte Maturation","Intranasal Nafarelin Compared to Subcutaneous Triptorelin for Triggering Final Oocyte Maturation in Ovarian Stimulation: a Non-inferiority Randomised Controlled Clinical Trial","INFORM","Inclusion Criteria:\n\n* Women undergoing fertility preservation cycles with oocyte cryopreservation\n* Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s)\n* BMI 18 - 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to either of the study drugs\n* Hypopituitarism\n* Known pituitary tumour\n* Contraindication to intranasal medication administration\n* Previous poor response to agonist trigger","40 Years",{"count":57,"type":21},154,[59],"PHASE4","This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.",[27],[63,64],"IVF","GnRH agonist","2026-06-02",{"date":67,"type":38},"2026-06-04",{"date":69,"type":21},"2026-06-15",{"date":71,"type":21},"2028-01-15",{"name":73,"class":45},"Fundacion Dexeus",5,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100277733","pregnancy-and-fertility-registry-100277733","NCT02895165","PREgnancy and FERtility Registry","An Italian Multicenter Prospective Cohort Study on Fertility Preservation and Pregnancy Issues in Young Breast Cancer Patients: PREgnancy and FERtilty (PREFER)","PREFER","Inclusion Criteria:\n\n* breast cancer diagnosis\n* age between18 and 45 years (only for PREFER-FERTILITY)\n* have not received any radiation or chemotherapy for cancer before enrolment (only for PREFER-FERTILITY)\n* absence of metastatic disease (only for PREFER-FERTILITY)\n* diagnosis of breast cancer during pregnancy or within 1 year from the end of pregnancy or pregnancy after prior diagnosis and treatment for breast cancer (only for PREFER-PREGNANCY)\n* informed consent\n\nExclusion Criteria:\n\n* inability to provide written informed consent\n* stage IV disease at diagnosis (only for PREFER-FERTILITY)\n* serious psychiatric disorders",{"count":84,"type":21},1000,"15 Years","OBSERVATIONAL","The PREgnancy and FERtility (PREFER) study is a comprehensive program aiming to optimize care and improve knowledge around the topics of fertility preservation and pregnancy issues in young breast cancer patients. The program was initiated at the National Institute for Cancer Research, IRCCS AOU San Martino - IST in Genova (Liguria Region, Italy) and then it has been spread to other Italian Institutions under the umbrella of the Gruppo Italiano Mammella (GIM) study group. It is composed of two distinctive studies, one assessing fertility (i.e. PREFER-FERTILITY) and the other pregnancy (PREFER-PREGNANCY) issues. Hence, two different study protocols were developed under the umbrella of the PREFER registry.\n\nPREFER-FERTILITY aims to obtain and centralize data about the preferences and choices of young cancer patients on the fertility preservation strategies available in Italy. Furthermore, it aims to assess the outcomes of patients undergoing one or more strategies for fertility preservation in terms of success of the techniques (i.e. recovery of ovarian function, number of cryopreserved oocytes, post-treatment pregnancies) and safety (i.e. long-term survival outcomes).\n\nPREFER-PREGNANCY has two main objectives: 1) to obtain and centralize data on the management of breast cancer diagnosed during pregnancy, the obstetrical and paediatric care of children born after prior in utero exposure to anticancer treatments, and the long-term survival outcomes of these patients; 2) to obtain and centralize data on the clinical outcomes of breast cancer survivors that achieve a pregnancy after prior diagnosis and treatment of breast cancer.",[89,90,27],"Breast Neoplasms","Pregnancy",[92,32,93],"breast neoplasms","pregnancy","RECRUITING","2026-04-29",{"date":97,"type":38},"2026-04-30",{"date":99,"type":4},"2012-11",{"date":101,"type":21},"2032-11",{"name":103,"class":45},"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",23,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100634933","ovarian-tissue-cryopreservation-combined-with-oocyte-cryopreservation-versus-oocyte-cryopreservation-alone-100634933","NCT07546123","Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone","Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone: an Observational Study in Oncology Patients","Inclusion Criteria:\n\n* Patient with oncological disease eligible for potentially gonadotoxic therapy\n* BMI ≥ 17.5 kg\u002Fm² and ≤ 32 kg\u002Fm²\n* Age ≥ 18 years and ≤ 46 years\n\nExclusion Criteria:\n\n* Hypersensitivity to one or more of the active substances used during ovarian stimulation treatment\n* Positive for HBV, HCV, HIV, or Treponema pallidum\n* Lack of oncological clearance","46 Years",{"count":114,"type":21},127,"Fertility preservation is a crucial aspect of care for oncological patients undergoing gonadotoxic treatments such as chemotherapy, radiotherapy, or surgery, which can significantly reduce ovarian reserve and cause infertility or premature menopause. Among available techniques, oocyte cryopreservation is well-established with high survival rates but requires controlled ovarian stimulation and may not be suitable for prepubertal patients or those needing urgent cancer therapy. Ovarian tissue cryopreservation offers advantages by preserving a larger number of primordial follicles, can be performed anytime in the menstrual cycle regardless of age, and also helps restore ovarian endocrine function.\n\nCombining ovarian tissue cryopreservation followed by oocyte cryopreservation may maximize fertility preservation by safeguarding more follicles and ensuring availability of mature oocytes.\n\nThis study will collect data from two patient groups:\n\nGroup 1: patients undergoing ovarian tissue cryopreservation followed by oocyte cryopreservation (combined treatment)\n\nGroup 2: patients undergoing oocyte cryopreservation alone.\n\nGroup assignment is based on planned gonadotoxic therapy and available time before treatment initiation, according to clinical practice.\n\nThe study aims to compare the number of oocytes retrieved per ovarian stimulation cycle between the two groups, along with the oocyte retrieval rate (number of oocytes retrieved\u002Fnumber of aspirated follicles), number of mature oocytes (metaphase II), incidence of moderate ovarian hyperstimulation syndrome within 7 days post-retrieval, and correlations between serum estradiol and luteinizing hormone levels on trigger day and oocyte yield.\n\nApproximately 127 patients aged 18 to 46 will be consecutively enrolled at the UO Gynecology and Human Reproduction Pathophysiology, IRCCS AOUBO Policlinico di Sant'Orsola. This is a cross-sectional, single-center, observational study with both retrospective and prospective enrollment. The retrospective period considered is from January 1, 2022, to the study start date. The study duration is 4 years and 3 months.",[117,27],"Oncological Disease","2026-04-20",{"date":120,"type":38},"2026-04-22",{"date":122,"type":38},"2025-08-25",{"date":124,"type":21},"2029-09",{"name":126,"class":45},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":133,"targetDuration":135,"studyType":86,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":46},"100634934","ovulation-induction-with-gnrh-analogue-or-dual-trigger-100634934","NCT07546136","Ovulation Induction With GnRH Analogue or Dual Trigger?","Inclusion Criteria:\n\n* Patient with oncological disease eligible for potentially gonadotoxic therapy\n* BMI ≥ 17.5 kg\u002Fm² and ≤ 32 kg\u002Fm²\n* Age ≥ 18 years and ≤ 46 years\n* AMH \\> 1.00 ng\u002FmL\n* Obtaining written informed consent to participate in the study and for data processing\n\nExclusion Criteria:\n\n* Hypersensitivity to one or more of the active substances used during the treatment",{"count":134,"type":21},200,"2 Weeks","Most medically assisted procreation (ART) techniques, including oocyte cryopreservation for fertility preservation, involve controlled ovarian stimulation. This procedure uses exogenous hormones, primarily follicle-stimulating hormone (FSH), to promote the development of multiple ovarian follicles in a single menstrual cycle. Once follicles reach a suitable number and size, oocyte retrieval (pick-up) is scheduled after pharmacological ovulation induction.\n\nHuman chorionic gonadotropin (hCG) has been routinely used for ovulation induction, but a common complication is ovarian hyperstimulation syndrome (OHSS). Studies have shown that in antagonist protocols, using a gonadotropin-releasing hormone agonist (GnRH-a) instead of hCG reduces OHSS risk. However, GnRH-a triggers luteal phase dysfunction, likely due to depletion of pituitary LH reserves and lack of LH-like activity (present in hCG), resulting in lower clinical pregnancy rates and occasionally very low oocyte yield.\n\nTo maximize oocyte retrieval and minimize OHSS risk, a combined \"dual trigger\" approach using both GnRH-a and hCG has been proposed, leveraging benefits of both agents.\n\nCurrently, limited data exist regarding the optimal ovulation induction strategy in oncological patients undergoing fertility preservation via oocyte cryopreservation before gonadotoxic therapy, where maximizing outcomes and minimizing complications is critical.\n\nThis study aims to compare the number of oocytes retrieved per cycle in oncological patients undergoing fertility preservation with ovulation induced by either GnRH-a alone or dual trigger (GnRH-a + hCG). It will also assess the oocyte retrieval rate (number of oocytes retrieved\u002Fnumber of follicles aspirated), number of mature oocytes, and incidence of moderate OHSS within 7 days post-retrieval in both groups. Additionally, it will explore correlations between serum estradiol (E2) and luteinizing hormone (LH) levels on the trigger day and oocyte yield.\n\nApproximately 200 patients aged ≥18 years will be consecutively enrolled over 2 years and 2 months. Retrospective period considered: from January 1, 2023, to the study initiation date. Patients will be assigned by clinicians to one of two groups based on clinical characteristics:\n\nGroup 1: Ovulation induced with 0.2 mg subcutaneous triptorelin (Decapeptyl®)\n\nGroup 2: Ovulation induced with 0.2 mg subcutaneous triptorelin plus 1000-5000 IU urinary hCG (Gonasi®)\n\nTreatment follows standard clinical practice.",[117,27],{"date":120,"type":38},{"date":140,"type":38},"2025-04-07",{"date":142,"type":21},"2027-04-03",{"name":126,"class":45},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":164,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":46},"100634727","decision-aid-for-elective-egg-freezing-100634727","NCT07543445","Decision Aid for Elective Egg Freezing","Knowledge, Decision-making, and Oocyte Cryopreservation Outcomes in Taiwanese Women Considering Elective Egg Freezing: a Randomized Controlled Trial","DAEEF","Inclusion Criteria:\n\n* Women aged 20 years or older.\n* Currently considering elective egg freezing (EEF).\n* Able to communicate and read Chinese fluently.\n* Have access to the internet and a mobile device (smartphone, tablet, or computer) to complete online questionnaires.\n\nExclusion Criteria:\n\n* Individuals who have previously completed oocyte cryopreservation.\n* Women undergoing fertility preservation due to malignancy (i.e., breast cancer).\n* Postmenopausal women.","20 Years",{"count":154,"type":21},120,[24],"The goal of this clinical trial is to evaluate whether a culturally tailored decision aid can improve decision-making and clinical outcomes for Taiwanese women considering elective egg freezing.\n\nThe main questions it aims to answer are:\n\nDoes the decision aid improve women's knowledge about elective egg freezing and help clarify their personal values? Does the decision aid reduce decision regret and psychological distress after making a decision about egg freezing?\n\nResearchers will compare women who use the decision aid with those who receive standard counseling to see if the tool improves knowledge, reduces distress and regret, and leads to better clinical outcomes (such as completing egg freezing or achieving a higher number of frozen oocytes).\n\nParticipants will:\n\n* Complete questionnaires assessing their baseline knowledge, attitudes, and values regarding egg freezing\n* Receive either the decision aid or standard counseling\n* Complete follow-up questionnaires to assess knowledge, distress, and decision regret\n* Have their clinical outcomes recorded, including whether they undergo egg freezing and the number of oocytes retrieved and frozen",[158,159,160,161,162,163,27],"Elective Egg Freezing","Oocyte Cryopreservation","Decision Aid","Egg Freezing","Shared Decision Making","Assisted Reproductive Technology",[165,166,32,167,168,169,170],"elective egg freezing","planned oocyte cryopreservation","decision aid","shared decision making","assisted reproductive technology","randomized controlled trial","2026-04-15",{"date":173,"type":38},"2026-04-21",{"date":175,"type":21},"2026-04-13",{"date":177,"type":21},"2031-12-31",{"name":179,"class":45},"National Taiwan University Hospital",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100610290","hormonal-optimization-late-vs-immediate-start-after-discontinuation-of-oral-contraceptives-in-assisted-reproductive-technology-holiday-100610290","NCT07225660","Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)","A Randomized Blinded Controlled Trial Assessing Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)","HOLIDAY","Inclusion Criteria:\n\n1. Ovary-bearing individuals 18 to 40 years of age.\n2. BMI \\\u003C 40 kg\u002Fm2\n3. Non-smoker for at least 3 months prior to study enrollment.\n\nExclusion Criteria:\n\n1. BMI greater than or equal to 40 kg\u002Fm2\n2. Current Smoker\n3. Any contraindications to ovarian stimulation or outpatient egg retrieval under anesthesia",{"count":189,"type":21},394,[24],"HOLIDAY is a two-arm, parallel-group, multi-center, randomized trial in which subjects undergoing planned oocyte cryopreservation will be randomized to receive either a 2-month pause of Combined Hormonal Contraceptives (CHC) or immediate start (without a pause).",[27],[166],"2026-02-26",{"date":196,"type":38},"2026-03-02",{"date":198,"type":38},"2026-02-25",{"date":200,"type":21},"2027-07-01",{"name":202,"class":45},"Shady Grove Fertility Reproductive Science Center",3,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":211,"minAge":17,"maxAge":212,"enrollmentInfo":213,"targetDuration":215,"studyType":86,"phases":4,"briefSummary":216,"conditions":217,"keywords":229,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":46},"100616933","long-term-evaluation-of-fertility-preservation-options-in-women-in-cancer-remission-or-haematological-pathology-100616933","NCT07312058","Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology","FERT-ISSUES","Inclusion Criteria:\n\n* Women\n* Aged between 18 and 47 years\n* Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment\n* Having undergone a medical fertility preservation consultation\n* Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine\n* Currently in remission\n* Having expressed non-opposition to participation in the study\n\nExclusion Criteria:\n\n* Absence of remission\n* Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)\n* Decline to participate in the study","ALL","47 Years",{"count":214,"type":21},102,"1 Day","Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.\n\nWomen of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.\n\nHowever, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.\n\nThis project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.\n\nThis work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).\n\nIts objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.\n\nThis work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.",[27,218,219,220,221,222,163,223,224,225,226,227,228],"Cancer Remission","Reproductive Outcomes","Reproductive Health","Oncology","Fertility Counseling","Psychological Impact","Fertility Observatory","Patient Follow-up","Female Cancer Survivors","Fertility Preservation Techniques","Live Birth Rate",[230,231,232,233,221,234,235,236,237,238,239,240,241],"Fertility preservation","Cancer remission","Reproductive outcomes","Reproductive health","Fertility counseling","Assisted reproductive technology","Psychological impact","Fertility observatory","Patient follow-up","Female cancer survivors","Fertility preservation techniques","Live birth rate","2026-01-15",{"date":244,"type":38},"2026-01-16",{"date":246,"type":21},"2025-12-17",{"date":248,"type":21},"2027-01",{"name":250,"class":45},"Centre Hospitalier Universitaire, Amiens",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":46},"100529596","phase-4-ppos-progestin-primed-ovarian-stimulation-and-corifollitropin-alfa-cfa-cross-over-study-100529596","NCT06175832","PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study","P-CCROSS","Prescreening: Clarification: Pre-screening might be performed to identify women with AFC \\> 5 and AMH \\> 1.1 ng\u002Fml (Bologna criteria, AFC and AMH values are valid for one year).\n\nInclusion criteria for:\n\n* Group 1: indication for oocyte cryopreservation\n* Group 2: indication for IVF\u002FICSI and PGT-A\n\nInclusion criteria for both groups:\n\n* First ovarian stimulation cycle\n* Aged ≥ 18 and \\\u003C 41 years old at the time of first OPU\n\nExclusion Criteria:\n\n* contra-indication for ovarian stimulation\n* expected poor ovarian response (Bologna Criteria)\n* PCOS patients\n* refusal to fill out questionnaires before, during and after treatment\n* simultaneous participation in another clinical study\n* untreated and uncontrolled thyroid dysfunction;\n* current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy;\n* pregnant or breastfeeding women. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.",{"count":260,"type":21},60,[59],"P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH\u002FGnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA\u002FPPOS versus rFSH\u002FGnRH ovarian stimulation cycles.",[264,265,266,27],"Ovarian Stimulation","Quality of Life","Preimplantation Genetic Testing","2025-12-18",{"date":269,"type":38},"2025-12-26",{"date":271,"type":38},"2025-01-27",{"date":273,"type":21},"2027-12-31",{"name":275,"class":45},"University Hospital, Ghent",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":18,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":290,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":46},"100175494","cryopreservation-of-ovarian-tissue-100175494","NCT01558544","Cryopreservation of Ovarian Tissue","Cryopreservation of Ovarian Tissue for Potential In Vitro Maturation or Autologous Transplantation","Inclusion Criteria:\n\n* Females 0-45 years of age who are premenopausal\n* Treatment plan that will likely result in premature menopause or premature ovarian failure\n* This includes patients receiving:\n* Cancer treatment with abdominal pelvic irradiation and\u002For high dose chemotherapy\n* Surgery that requires removal of ovaries for medical condition or disease, e.g. Prophylactic oophorectomy in BRCA patients\n* Patient is unable or unwilling to pursue fertility preservation by freezing oocytes or embryos.\n* Previous treatment for cancer is acceptable if patient still has ovarian function\n* Patient is medically stable enough to undergo surgery (cleared for anesthesia)\n\nExclusion Criteria:\n\n* Patients not meeting the above criteria\n* Patients who have not received medical clearance from their physicians to undergo surgery\n* Patients already experiencing menopause.",{"count":284,"type":21},300,[24],"The study hopes to contribute to the development of technologies of ovarian tissue freezing-thawing and in vitro maturation of immature eggs such that a person at risk for premature ovarian failure might be able to conceive a genetically related child.",[288,289,27],"Cancer","Risk of Premature Ovarian Failure",[291,292,230,293],"Ovarian tissue cryopreservation","Ovarian tissue transplantation","Risk of premature ovarian failure","2025-12-09",{"date":296,"type":38},"2025-12-10",{"date":298,"type":38},"1997-04",{"date":300,"type":21},"2029-10-31",{"name":302,"class":45},"Weill Medical College of Cornell University",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":211,"minAge":310,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":330},"100473349","phase-3-evaluation-of-a-telehealth-oncofertility-care-intervention-in-adolescent-and-young-adult-cancer-patients-100473349","NCT05443737","Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients","Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients: a Stepped Wedge Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Newly diagnosed cancer or cancer relapse\n* Primary language English or Spanish\n* Receiving oncology care at participating clinical sites\n* Ages 0 to 42 years if female\n* Ages 0 to 50 years if male\n\nExclusion Criteria:\n\n* Non-melanoma skin cancer, because primary treatment is excision with no infertility risk\n* Metastatic\u002FStage IV non-thyroid solid tumors, because of poor prognosis","0 Years","50 Years",{"count":313,"type":21},2800,[315],"PHASE3","The purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the intervention is implemented. The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant oncofertility care.",[288,27],[319,230,320],"Oncofertility","Adolescent and young adult cancer","2025-11-25",{"date":323,"type":38},"2025-12-03",{"date":325,"type":38},"2022-01-01",{"date":327,"type":21},"2027-08-31",{"name":329,"class":45},"University of California, San Diego",4,{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":341,"conditions":342,"keywords":346,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":46},"100598929","surgical-and-obstetric-outcomes-in-endometrial-adenocarcinoma-and-atypical-endometrial-hyperplasia-with-conservative-treatment-100598929","NCT07077876","Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment","Surgical and Obstetric Outcomes in Patients With Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia Undergoing Conservative Treatment","CHOICE","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histological diagnosis of endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH).\n* Patients who underwent conservative treatment with hysteroscopic resection at the CLASS Hysteroscopy Center, performed by a single experienced surgeon (U.C.).\n* Patients treated conservatively due to medical contraindications to radical surgery (e.g., severe comorbidities).\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patients with other known causes of infertility.\n* Patients with non-endometrioid histological subtypes of endometrial adenocarcinoma.\n* Patients under 18 years of age.\n* Patients who did not provide informed consent for participation.",{"count":340,"type":21},100,"This observational study aims to evaluate the obstetric and oncological outcomes of patients diagnosed with endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH) who underwent conservative treatment at the CLASS Hysteroscopy Center of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. Eligible patients include women who received hysteroscopic surgery and hormonal therapy either to preserve fertility or due to medical contraindications to standard radical surgery. Follow-up lasts 12 months.",[343,344,27,345],"Endometrial Adenocarcinoma","Endometrial Hyperplasia","Conservative Treatment Therapy",[347,348,349,350,351,219],"Endometrial Cancer","Atypical Endometrial Hyperplasia","Fertility-Sparing Treatment","Hysteroscopy","Progestin Therapy","2025-07-12",{"date":354,"type":38},"2025-07-22",{"date":356,"type":38},"2025-06-20",{"date":358,"type":21},"2026-01-20",{"name":360,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":369,"studyType":86,"phases":4,"briefSummary":370,"conditions":371,"keywords":377,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":4},"100567757","clinical-studies-of-endometrial-cytology-and-cervical-methylation-assays-in-endometrial-cancer-screening-and-fertility-preservation-evaluation-100567757","NCT06672341","Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation","A Prospective, Open, Observational Clinical Study on Endometrial Cytology and Cervical Methylation Testing for Screening and Evaluating Fertility-Sparing Treatment in Endometrial Cancer","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for the study:\n\n  1. Color Doppler ultrasound indicating intrauterine masses or abnormal endometrial thickening (for postmenopausal women not receiving hormone replacement therapy, endometrial thickness \\>5mm).\n  2. Patients undergoing follow-up and efficacy evaluation for fertility-sparing treatment of endometrial cancer or atypical endometrial hyperplasia.\n  3. Patients with endometrial thickening following endocrine therapy for breast cancer.\n  4. Signed informed consent form.\n  5. Good compliance.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  1. Diagnosed with cervical cancer.\n  2. Severe systemic complications preventing hysteroscopy.\n  3. Pregnant or recent history of miscarriage.\n  4. Acute genital tract infection or pelvic inflammatory disease.\n  5. Insertion of an intrauterine device.\n  6. Sexual activity, vaginal douching, or medication use within 24 hours.",{"count":134,"type":21},"1 Year","The current study aims to assess high-risk patients using both liquid-based cytology and cervical methylation testing. The results will be compared with the traditional hysteroscopic pathological findings to determine the sensitivity and specificity of these methods for early detection of endometrial cancer, thereby evaluating their potential application in early screening.\n\nPrimary Objectives：\n\n1. To evaluate the sensitivity, specificity, and accuracy of endometrial cytology for screening endometrial cancer.\n2. To assess the sensitivity, specificity, and accuracy of methylation testing for screening endometrial cancer.\n3. To perform further molecular testing on tissue samples obtained from endometrial cytology and cervical methylation tests, aiming to explore early screening-sensitive indicators.\n\nSecondary Objectives：\n\n1. To determine the value of endometrial cytology in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.\n2. To assess the value of methylation testing in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.",[347,372,373,27,374,375,376],"Methylation","Cytology","Screening Tool","Liquid Biopsy","Non-invasive",[347,378,379,373,380,381,382,383,384],"screening","methylation","Liquid-Based Cytology Test","Early diagnosis","fertility-sparing","liquid biopsy","non-invasive","2024-11-03",{"date":387,"type":38},"2024-11-05",{"date":389,"type":21},"2024-11-04",{"date":391,"type":21},"2026-02-01",{"name":393,"class":45},"Yulan Ren",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":417},"100538302","phase-2-neoadjuvant-chemotherapy-plus-camrelizumab-for-figo-stage-ib1-cervical-cancer-100538302","NCT06289062","Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer","Neoadjuvant Chemotherapy Plus Camrelizumab (NACI Therapy) for Fertility Preservation in FIGO Stage IB1 Cervical Cancer","Inclusion Criteria:\n\n1. Clinical diagnosis of stage IB1 cervical cancer after gynecologic examination and MRI evaluation by the investigator (FIGO 2018);\n2. Pathologically confirmed diagnosis of cervical squamous cell carcinoma;\n3. Transformation zone of TZ1 or TZ2 (IFCPC 2011);\n4. Positive PD-L1 expression by preoperative pathology, i.e., Combined Positive Score (CPS) ≥1;\n5. Patient age ≥18 years and ≤45 years;\n6. ECOG score ≤1;\n7. Laboratory tests: white blood cell (WBC) ≥3. 5×109\u002FL, Neutrophil (NEU) ≥1. 5×109\u002FL, platelet (PLT) ≥100×109\u002FL, serum bilirubin ≤1.5 times the upper limit of normal, aminotransferase ≤1.5 times the upper limit of normal, and blood urea nitrogen （BUN) and Cr ≤normal;\n8. Have a strong desire to give birth;\n9. Willing to sign the informed consent form, including compliance with the requirements and restrictions listed in the informed consent form and program.\n\nExclusion Criteria:\n\n1. History of infertility, including those with infertility due to tubal or (and) husband;\n2. Any active autoimmune disease or history of autoimmune disease requiring systemic treatment, including, but not limited to, autoimmune hepatitis, interstitial pneumonitis, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, thyroid dysfunction, asthma requiring bronchodilator intervention;\n3. Prior treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies; known hypersensitivity to any component of the study medication or other monoclonal antibodies;\n4. History of human immunodeficiency virus (HIV) infection or known active hepatitis B or C;\n5. Use of immunosuppressive drugs or systemic corticosteroid therapy for immunosuppression (\\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to study dosing;\n6. History of primary malignancy or receipt of chemotherapy or pelvic radiation;\n7. Concurrent participation in other clinical trials;\n8. Pregnant or breastfeeding female patients; subjects must agree to use effective contraception during study treatment, within 5 months of last use of immune check inhibitors, within 6 months of last use of chemotherapeutic agents, and if there is no confirmation that the lesion has been removed or that the pathology is in remission;\n9. Uncontrolled co-morbidities, including but not limited to New York Heart Association (NYHA) class 2 or higher, severe\u002Funstable angina pectoris, myocardial infarction within ≤ 6 months prior to study drug administration, severe arrhythmias requiring medication or intervention; difficult-to-control hypertension; and cerebral vascular accidents or brain disorders within ≤ 6 months prior to study drug administration, or those with adjudicated abnormal behavioral skills; hematologic disorders: coagulation abnormalities (INR \\> 2. 0, Prothrombin time (PT) \\> 16s), bleeding tendency, or undergoing thrombolytic or anticoagulant therapy; abnormalities in hepatic or renal development or a history of surgery; and any active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study drug;\n10. Treatment with live or attenuated vaccine within 4 weeks prior to the first dose of study drug; inactivated seasonal influenza virus vaccine is permitted;\n11. Patients who have received a previous allogeneic bone marrow or solid organ transplant;\n12. Drug and\u002For alcohol abuse;\n13. Patients who, in the opinion of the investigator, are unlikely to comply with the study procedures, restrictions, and requirements may not participate in this study.",{"count":402,"type":21},40,[404],"PHASE2","This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, EFS and OS.",[407,408,27],"Cervical Cancer","Neoadjuvant Chemoimmunotherapy","2024-11-01",{"date":387,"type":38},{"date":412,"type":38},"2024-05-08",{"date":414,"type":21},"2030-12-01",{"name":416,"class":45},"Tongji Hospital",2,{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":18,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":4},"100552063","fertility-sparing-therapy-for-patients-with-stage-ia-g2-endometrial-cancer-100552063","NCT06468215","Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer","Inclusion Criteria:\n\n* Endometrioid adenocarcinoma G2, diagnosis by pathological.\n* The lesion is limited to the endometrium.\n* FIGO (2009) staging is IA.\n* Age less than 45.\n* Strongly request to preserve fertility.\n* Sign informed consent.\n\nExclusion Criteria:\n\n* The tumor has invaded the muscle layer.\n* FIGO (2009) stage IB or higher.\n* Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer\n* There are malignant tumors in other systems.\n* Have contraindications for conservative treatment or drug use.\n* Have been judged by the researcher to be unsuitable for childbearing.",{"count":425,"type":21},16,[24],"Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.",[429,27],"Carcinoma, Endometrioid",[431,432,433],"endometrial cancer","fertility-sparing treatment","grade 2","2024-07-13",{"date":436,"type":38},"2024-07-16",{"date":438,"type":21},"2024-07",{"date":440,"type":21},"2028-10",{"name":442,"class":45},"Peking University People's Hospital",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":211,"minAge":451,"maxAge":311,"enrollmentInfo":452,"targetDuration":454,"studyType":86,"phases":4,"briefSummary":455,"conditions":456,"keywords":461,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":46},"100507258","impact-of-gonadotoxic-therapies-on-fertility-100507258","NCT05885048","Impact of Gonadotoxic Therapies on Fertility","FertiTOX - Platform for Fertility Related Gonadotoxicity of Cancer Therapies","FertiTOX","Inclusion Criteria:\n\n* Patients with cancer or with benign reasons undergoing chemotherapy and\u002For radiotherapy of the pelvis (females) and the testicles (males) and\u002For immune therapy;\n* Willing to participate;\n* Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults);\n* Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males).\n\nExclusion Criteria:\n\n* Missing consent;\n* Language barrier.","14 Years",{"count":453,"type":21},7000,"10 Years","The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer.\n\nThe main questions it aims to answer are:\n\n* in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve);\n* in males, if cancer therapies reduce sperm concentration (sperm quality).",[288,457,27,458,459,460],"Fertility Issues","Toxicity Due to Chemotherapy","Toxicity Due to Radiotherapy","Effects of Immunotherapy",[462],"Gonadotoxicity","2024-05-31",{"date":465,"type":38},"2024-06-03",{"date":467,"type":38},"2023-12-01",{"date":469,"type":21},"2038-12-31",{"name":471,"class":45},"Michael von Wolff",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100533602","phase-3-fsh-and-lh-versus-fsh-alone-for-ovarian-stimulation-in-non-hormone-sensitive-onco-fertility-patients-100533602","NCT06227949","FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients","FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients: an Exploratory Randomized Controlled Trial","Inclusion Criteria:\n\n* Between the ages of 18 and 40.\n* Undergoing IVF for fertility preservation (freezing all oocytes or embryos)\n* Diagnosed with a non-hormone sensitive malignancy (malignancy other than breast, uterine and ovarian cancer)\n* GnRH antagonist protocol (standard of care for all fertility preservation patients)\n\nExclusion Criteria:\n\n* Any contraindication to treatment with gonadotropins (including medical history or risk factors for TE, hypersensitivity to gonadotropins or to any of the excipients).\n* Congenital hypogonadotropic hypogonadism unrelated to the oncological condition.\n* Previous adverse or allergic reaction to luteinizing hormone or any of its drug components.\n* Had prior radiotherapy to the abdomen or pelvis\n* Prior chemotherapy\n* Prior history of deep vein thrombosis, or pulmonary embolism\n* Patients with a diagnosis of hormone sensitive cancer including ovarian, uterine, or mammary carcinoma\n* Patients with uncontrolled thyroid or adrenal failure\n* Patients with active, untreated tumors of the hypothalamus and pituitary gland\n* Patients who are lactating\n* Patients with a known diagnosis of primary ovarian failure\n* Previous participant of this study",{"count":20,"type":21},[315],"Fertility preservation has been performed before the initiation of cancer therapy as cancer therapy is known to be toxic for ovarian function. However, recent studies have shown that ovarian function is reduced in cancer patients even before they start cancer therapy. Reduced ovarian function has been shown by these patients having fewer mature oocytes (female eggs) and lower peak levels of estradiol (a type of estrogen hormone important for fertility). Other studies have shown that in some types of cancers, cancer patients have lower levels of anti-Müllerian hormone, which is a hormone measured to assess how many eggs patient has remaining in the body. Because of these poorer fertility markers shown in cancer patients prior to therapy, some doctors and researchers believe that alternative medications for stimulating ovaries may prove to be beneficial for stimulating the ovaries during fertility preservation.\n\nCurrently, luteinizing hormone injections are approved by Health Canada for patients with hypothalamic dysfunction. Hypothalamic dysfunction is a condition whereby lower levels of fertility hormones are produced because of brain dysfunction. Other reasons luteinizing hormone is used in clinical practice is in patients with poor ovarian reserve and patients who are older.\n\nRecent research studies have suggested that some oncology patients may be poor responders prior to cancer therapy because of their underlying disease. The exact reasons for this poor response are not known. However, some researchers believe it may be related to the interactions between the brain and fertility organs, similar to patients with hypothalamic dysfunction. Because of this possible similarity to patients with hypothalamic dysfunction, adding luteinizing hormone to follicle-stimulating hormone (the hormone typically used for ovarian stimulation) may be beneficial for fertility preservation. Studies have also shown improved fertility outcomes with the addition of luteinizing hormone in non-cancer patients who were previously known to be poor responders to ovarian stimulation.\n\nThe clinical trial team is aiming to conduct a randomized controlled trial to evaluate the safety and efficacy of luteinizing hormone in non-hormone sensitive cancer patients (patients with cancer other than the breast, ovary or uterus).",[27],[63,32,484,485,486,487],"oncofertility","rLH","FSH","cryopreservation","2024-01-18",{"date":490,"type":38},"2024-01-29",{"date":492,"type":21},"2024-02",{"date":494,"type":21},"2031-12",{"name":496,"class":45},"Ellen Greenblatt",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":506,"briefSummary":507,"conditions":508,"keywords":512,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":523,"locationsCount":46},"100511896","fertility-sparing-therapy-for-patients-with-stage-ia-endometrial-cancer-100511896","NCT05945407","Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","Establishment of a Network Platform for Fertility-sparing in Patients With Endometrial Cancer and Study on Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer.","Inclusion Criteria:\n\n* Stage IA (FIGO 2009) ;\n* Pathological diagnosis: endometrial adenocarcinoma G1-G2;\n* MRI or ultrasound: tumor limited to endometrium or invading less than 1\u002F2 of myometrium；\n* 18 years old ≤ Age ≤ 45 years old;\n* With a strong desire for fertility preservation；\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Complicated with any other malignancy；\n* Contraindications to conservative treatment；\n* Contraindications to progestin use;\n* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.",{"count":505,"type":21},57,[24],"The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1\u002F2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.",[509,510,511,429,27],"Endometrial Neoplasms","Endometrial Neoplasm Malignant","Endometrial Neoplasm Malignant Stage I",[513,514,515,347,516],"Fertility-sparing","Fertility-preserving","Endometrial Carcinoma","Indication Extension","2023-07-12",{"date":519,"type":38},"2023-07-14",{"date":521,"type":38},"2016-08-01",{"date":273,"type":21},{"name":442,"class":45},{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":16,"minAge":532,"maxAge":451,"enrollmentInfo":533,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":535,"conditions":536,"keywords":540,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":551},"100254767","amh-as-a-predictor-of-infertility-risk-in-children-with-cancer-chance-100254767","NCT02595255","AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)","Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal\u002FPubertal Cancer Patients","CHANCE","Inclusion Criteria:\n\n* Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005):\n\n  * High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation\n  * Moderate\u002FLow risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.\n  * No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.\n\nExclusion Criteria:\n\n* CNS (central nervous system) irradiation, cerebral tumour\n* Current or previous ovarian disease\u002Fsurgery\n* Familial history of premature ovarian failure (no iatrogenic or surgical origins)\n* Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic\u002Fcongenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction)\n* Genetic\u002Fcongenital disorders inducing mental retardation","3 Years",{"count":534,"type":21},275,"While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk.\n\nThe primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.",[27,537,538,539],"Lymphoma","Pediatrics Cancer","Gonadotropin-releasing Hormone Agonist",[541],"chemotherapy\u002FGnRH (gonadotropin-releasing hormone) analogues\u002Flymphoma\u002Fchildren\u002Ffertility","2020-04-30",{"date":544,"type":38},"2020-05-04",{"date":546,"type":38},"2014-04",{"date":548,"type":21},"2036-12",{"name":550,"class":45},"Erasme University Hospital",10]